Iconic, which develops treatments for eye disorders, has now raised almost $32m after securing $20m in is series B round.
Lundbeckfond Ventures, an investment subsidiary of Denmark-based pharmaceutical company Lundbeck, has participated in a $20m funding round for US-based biopharmaceutical company Iconic Therapeutics.
The series B round also included investors MPM Capital and H.I.G Bioventures. As part of the investment deal Lundbeckfond’s Johan Kordel, alongside MPM’s Todd Foley and H.I.G’s Bruce Robertson, will join Iconic’s board of directors. MPM partner William Greene will be appointed as Iconic’s CEO.
The investment will allow Iconic to further develop its treatment for eye-disorder…
